- Home
- AVDX vs ARVN Comparison
AVDX vs ARVN Comparison
Compare AVDX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- ARVN
- Stock Information
- Founded
- AVDX 2000
- ARVN 2015
- Country
- AVDX United States
- ARVN United States
- Employees
- AVDX N/A
- ARVN N/A
- Industry
- AVDX EDP Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- ARVN Health Care
- Exchange
- AVDX Nasdaq
- ARVN Nasdaq
- Market Cap
- AVDX 1.6B
- ARVN 1.7B
- IPO Year
- AVDX 2021
- ARVN 2018
- Fundamental
- Price
- AVDX $11.50
- ARVN $24.81
- Analyst Decision
- AVDX Hold
- ARVN Strong Buy
- Analyst Count
- AVDX 15
- ARVN 13
- Target Price
- AVDX $11.63
- ARVN $61.08
- AVG Volume (30 Days)
- AVDX 2.1M
- ARVN 639.2K
- Earning Date
- AVDX 11-06-2024
- ARVN 10-30-2024
- Dividend Yield
- AVDX N/A
- ARVN N/A
- EPS Growth
- AVDX N/A
- ARVN N/A
- EPS
- AVDX N/A
- ARVN N/A
- Revenue
- AVDX $427,566,000.00
- ARVN $161,100,000.00
- Revenue This Year
- AVDX $17.55
- ARVN $237.44
- Revenue Next Year
- AVDX $10.57
- ARVN N/A
- P/E Ratio
- AVDX N/A
- ARVN N/A
- Revenue Growth
- AVDX 17.84
- ARVN 1.07
- 52 Week Low
- AVDX $7.38
- ARVN $21.17
- 52 Week High
- AVDX $13.56
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- AVDX 76.40
- ARVN 45.51
- Support Level
- AVDX $11.23
- ARVN $24.38
- Resistance Level
- AVDX $11.55
- ARVN $27.00
- Average True Range (ATR)
- AVDX 0.28
- ARVN 1.56
- MACD
- AVDX -0.02
- ARVN 0.02
- Stochastic Oscillator
- AVDX 88.23
- ARVN 52.83
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.